NORDEA INVESTMENT MANAGEMENT AB
Position in PTGX — Protagonist Therapeutics, Inc
CIK 1218210
STOCKHOLM, V7
Position in PTGX
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$7,963,286
+$2,501,354 QoQ
Shares Held
64,964
+25.4% QoQ
Ownership
0.100%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#79
of 341 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026NORDEA INVESTMENT MANAGEMENT AB holds $503,679,873 across 20 Biotechnology names. PTGX ranks #8 (1.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
363,479 | $226,643,694 | |
| 2 | RPRX |
Royalty Pharma plc
|
2,576,772 | $144,479,604 | |
| 3 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
284,175 | $23,163,103 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
49,943 | $15,786,482 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
30,496 | $15,148,278 | |
| 6 | EXEL |
Exelixis, Inc.
|
210,314 | $11,443,184 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
26,913 | $8,101,620 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
This page
|
64,964 | $7,963,286 |
All Filings in PTGX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $7,963,286 | 64,964 | Shares | Defined | 2026-08-05 | |
| 2026-03-31 | $5,461,932 | 51,821 | Shares | Defined | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||